Exscientia announces first-in-human study for bristol myers squibb in-licensed pkc theta inhibitor, exs4318

Oxford, england--( business wire )--exscientia plc (nasdaq: exai) today announced that exs4318 ('4318) a compound precision designed by exscientia and in-licensed by bristol myers squibb in august 2021, has entered phase 1 clinical trials in the united states. the compound is in development for immunology & inflammation (i&i) indications. bristol myers squibb will oversee the clinical and commercial development and exscientia is eligible for milestone payments and, if approved, tiered royalties on net product sales.
EXAI Ratings Summary
EXAI Quant Ranking